2019 -- H 5558 | |
======== | |
LC001879 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2019 | |
____________ | |
A N A C T | |
RELATING TO BUSINESSES AND PROFESSIONS - PHARMACIES | |
| |
Introduced By: Representatives Tanzi, Fogarty, Cortvriend, Carson, and Hawkins | |
Date Introduced: February 27, 2019 | |
Referred To: House Health, Education & Welfare | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Chapter 5-19.1 of the General Laws entitled "Pharmacies" is hereby |
2 | amended by adding thereto the following section: |
3 | 5-19.1-34. Tobacco cessation therapy prescriptive authority. |
4 | (a) A pharmacist who is licensed pursuant to this chapter and who meets the requirements |
5 | of this section may prescribe and dispense first line tobacco cessation drug therapies to a qualified |
6 | patient pursuant to rules adopted by the board of pharmacy. |
7 | (b) For the purposes of this section, "qualified patient" means a patient who: |
8 | (1) Is at least eighteen (18) years of age; |
9 | (2) Is willing to participate in a structured tobacco cessation program consisting of an |
10 | initial evaluation and appropriate follow-up visits with the pharmacist prescribing tobacco |
11 | cessation products; |
12 | (3) Has been educated on symptoms of nicotine toxicity, common and/or severe adverse |
13 | effects of prescribed medication(s), and when to seek medical treatment. |
14 | (c) Prior to prescribing tobacco cessation products, the pharmacist must successfully |
15 | complete a course on tobacco cessation therapy taught by a provider accredited by the |
16 | Accreditation Council for Pharmacy Education or by a comparable provider recognized by the |
17 | board of pharmacy. |
18 | (d) The pharmacist may refer high risk patients or patients with an identified |
19 | contraindication to first line tobacco cessation drug therapies to the patient's primary care |
| |
1 | provider, as applicable, or to another provider, as appropriate. |
2 | (e) All pharmacists participating in prescribing therapy for tobacco cessation will follow |
3 | the US Department of Health and Human Services, Public Health Services, Clinical Practice |
4 | Guideline: Treating Tobacco Use and Dependence: 2008 Update (or subsequent updates as they |
5 | become available), or the most updated standard of care as approved by board of pharmacy. |
6 | (1) Pharmacists will implement the Five A's (ask, advise, assess, assist, arrange) to help |
7 | patients quit using all forms of tobacco. |
8 | (2) Pharmacists' services will include an educational component to include counseling on |
9 | medication therapies and cessation strategies as well as referral to sources provided by the Rhode |
10 | Island department of health. |
11 | (f) Notification of the patient screening, the prescription record and the follow-up care |
12 | plan shall be provided to the patient's primary care provider, as applicable, within five (5) |
13 | business days following the prescribing of a tobacco cessation product. |
14 | SECTION 2. This act shall take effect upon passage. |
======== | |
LC001879 | |
======== | |
| LC001879 - Page 2 of 3 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO BUSINESSES AND PROFESSIONS - PHARMACIES | |
*** | |
1 | This act would authorize a licensed pharmacist, who successfully completes a course on |
2 | tobacco cessation therapy, to prescribe and dispense tobacco cessation drug products to a |
3 | qualified patient pursuant to rules adopted by the board of pharmacy. The act would also provide |
4 | that in order for a willing patient to qualify, he or she must be 18 years of age, evaluated and |
5 | educated in the tobacco cessation products. |
6 | This act would take effect upon passage. |
======== | |
LC001879 | |
======== | |
| LC001879 - Page 3 of 3 |